Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Tax Provisions: 2009-2024

Historic Tax Provisions for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $6.5 million.

  • Ligand Pharmaceuticals' Tax Provisions rose 2764.83% to $23.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 6.10%. This contributed to the annual value of $6.5 million for FY2024, which is 33.44% down from last year.
  • Ligand Pharmaceuticals' Tax Provisions amounted to $6.5 million in FY2024, which was down 33.44% from $9.8 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Tax Provisions ranged from a high of $41.2 million in FY2022 and a low of -$5.3 million during FY2020.
  • Its 3-year average for Tax Provisions is $19.2 million, with a median of $9.8 million in 2023.
  • In the last 5 years, Ligand Pharmaceuticals' Tax Provisions crashed by 103.17% in 2020 and then spiked by 1,093.97% in 2022.
  • Ligand Pharmaceuticals' Tax Provisions (Yearly) stood at -$5.3 million in 2020, then rose by 21.82% to -$4.1 million in 2021, then soared by 1,093.97% to $41.2 million in 2022, then crashed by 76.13% to $9.8 million in 2023, then slumped by 33.44% to $6.5 million in 2024.